DK1082423T3 - Cyclin E2-gener og -proteiner - Google Patents

Cyclin E2-gener og -proteiner

Info

Publication number
DK1082423T3
DK1082423T3 DK99904337T DK99904337T DK1082423T3 DK 1082423 T3 DK1082423 T3 DK 1082423T3 DK 99904337 T DK99904337 T DK 99904337T DK 99904337 T DK99904337 T DK 99904337T DK 1082423 T3 DK1082423 T3 DK 1082423T3
Authority
DK
Denmark
Prior art keywords
cyclin
genes
proteins
polypeptides
disclosed
Prior art date
Application number
DK99904337T
Other languages
Danish (da)
English (en)
Inventor
Michael Brian Bass
Steven Roy Coats
Murray O Robinson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1082423T3 publication Critical patent/DK1082423T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK99904337T 1998-06-05 1999-01-28 Cyclin E2-gener og -proteiner DK1082423T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/092,770 US5973119A (en) 1998-06-05 1998-06-05 Cyclin E genes and proteins

Publications (1)

Publication Number Publication Date
DK1082423T3 true DK1082423T3 (da) 2006-02-13

Family

ID=22235079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99904337T DK1082423T3 (da) 1998-06-05 1999-01-28 Cyclin E2-gener og -proteiner

Country Status (10)

Country Link
US (4) US5973119A (de)
EP (1) EP1082423B1 (de)
JP (1) JP2002517196A (de)
AT (1) ATE310085T1 (de)
AU (1) AU752358B2 (de)
CA (1) CA2336261C (de)
DE (1) DE69928395T2 (de)
DK (1) DK1082423T3 (de)
ES (1) ES2252928T3 (de)
WO (1) WO1999063089A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933376B2 (en) 1998-09-23 2005-08-23 Pioneer Hi-Bred International, Inc. Cell cycle polynucleotides, polypeptides and uses thereof
US20050076404A1 (en) * 1999-02-12 2005-04-07 Pioneer Hi-Bred International, Inc. Cell cycle polynucleotides, polypeptides and uses thereof
US20030092890A1 (en) * 1999-07-28 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001240096A1 (en) * 2000-03-08 2001-09-17 Rebecca L. Dubowy Methods of diagnosing and monitoring endometrial glandular development
US20030143647A1 (en) * 2001-09-24 2003-07-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diagnostic methods and reagents
JP2007516230A (ja) * 2003-05-19 2007-06-21 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 心臓組織の変性を治療及び予防するための組成物及び方法並びにその用途
WO2007044033A2 (en) * 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
CA2660661A1 (en) * 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
EP3147665A1 (de) * 2005-12-22 2017-03-29 Abbott Molecular Inc. Verfahren und markerkombinationen zur untersuchung auf veranlagung von lungenkrebs
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
EP2309273B1 (de) * 2009-09-16 2016-05-18 ZEILLINGER, Robert Neue Tumormarkiererbestimmung
CN112625133A (zh) * 2021-01-14 2021-04-09 山西农业大学 一种cdk2纳米抗体及其应用
CN116217722B (zh) * 2023-03-22 2023-09-15 广东省第二人民医院（广东省卫生应急医院） 一种抗CyclinE蛋白的纳米抗体及编码基因和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3015417A1 (de) * 1980-04-22 1981-10-29 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von formteilen aus ungesaettigten polyesterharzen
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (de) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0401384B1 (de) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) * 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1993006123A1 (en) * 1991-09-20 1993-04-01 Fred Hutchinson Cancer Research Center Human cyclin e
US5489743A (en) * 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US6664107B1 (en) * 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1994028122A1 (en) * 1993-05-26 1994-12-08 Ontario Cancer Institute Transgenic mammals lacking expression of particular cd45 isoforms
ES2178654T3 (es) * 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
AU2770695A (en) * 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
JPH11506722A (ja) * 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
AU7015396A (en) * 1995-09-07 1997-03-27 Health Research Incorporated Cyclin e variants and use thereof
US5679559A (en) * 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
DK0938555T3 (da) * 1996-07-24 2005-05-23 Upjohn Co Konstruktioner og komplekser af cyclin E

Also Published As

Publication number Publication date
US20030078370A1 (en) 2003-04-24
CA2336261C (en) 2008-05-13
US6943238B2 (en) 2005-09-13
JP2002517196A (ja) 2002-06-18
US20050282150A1 (en) 2005-12-22
US7455963B2 (en) 2008-11-25
EP1082423A1 (de) 2001-03-14
DE69928395T2 (de) 2006-06-01
ATE310085T1 (de) 2005-12-15
US6165753A (en) 2000-12-26
AU2475499A (en) 1999-12-20
AU752358B2 (en) 2002-09-19
CA2336261A1 (en) 1999-12-09
US5973119A (en) 1999-10-26
WO1999063089A1 (en) 1999-12-09
DE69928395D1 (de) 2005-12-22
EP1082423B1 (de) 2005-11-16
ES2252928T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
WO1998021343A8 (en) Genes encoding telomerase proteins
EP1131333A4 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2000018914A3 (en) Novel dkr polypeptides
ATE415480T1 (de) B7l-1 moleküle
CY1112101T1 (el) Νευροτροφικοι παραγοντες
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
DK0939767T3 (da) Procin faktor VIII og hybrider deraf
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE544776T1 (de) Chimäre dna-bindeproteine
ATE484587T1 (de) Ldcam genannte moleküle
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
AU4981101A (en) Subtilisin variants
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
ATE439441T1 (de) Veränderte, fluoreszierende proteine
ATE280947T1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
FI971896A7 (fi) BMP-tyyppi II-reseptoria koodaava cDNA
BR9710919A (pt) Proteina purificada sr-p70
PT935652E (pt) Produtos de factor de crescimento de queratinocitos-2
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
DE69830074D1 (de) Humane sel-10 polypeptiden und dafur kodierende polynukleotiden